Core Insights - Polarean Imaging plc is gaining recognition for its innovative Xenon MRI platform, which is being highlighted at major respiratory medicine conferences, indicating its growing importance in clinical imaging and drug development [2][3][5] Group 1: Company Overview - Polarean Imaging is a commercial-stage medical imaging technology company focused on functional MRI of the lungs, aiming to improve lung health and address unmet medical needs for over 500 million patients with chronic respiratory diseases [10] - The company has developed the first and only hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW™, which is FDA-approved for evaluating lung ventilation in adults and pediatric patients aged 12 years and older [11][10] Group 2: Conference Participation - Polarean will be featured at the American Thoracic Society's 2025 Respiratory Innovation Summit and the ATS 2025 International Conference, showcasing its commitment to engaging with leaders in pulmonary medicine [1][5] - At the ATS 2025 International Conference, Xenon MRI will be presented in over 30 posters and presentations from more than 10 leading clinical sites, demonstrating its sustained momentum and expanding role in clinical care and trials [3][6] Group 3: Research and Development - The presentations at the conferences will cover a wide range of respiratory conditions, including asthma, COPD, COVID-19, and pulmonary arterial hypertension, highlighting the versatility of Xenon MRI [4][6] - The company emphasizes the importance of building partnerships and strengthening collaborations with clinicians, researchers, and patient advocates to advance the field of functional lung imaging [5][6]